|
|
|
The USITC releases its recommendations for USTR’s next steps on the COVID IP waiver. Plus, our coverage of the BIO Investor Forum continues. (664 words, 3 minutes, 19 seconds)
|
|
|
|
|
|
|
The BIO Investor Forum sessions started with a look at the state of investment—and what investors expect right now from early-stage companies. "Investors are now asking these companies to be a little bit later stage," said Jonathan Norris, Managing Director of HSBC Innovation. "You can be pre-clinical, but the round that you need to raise needs to get you into the clinic."
What investors want: a good story matched with solid milestones and a solid budget—which allowed Kevin Forrest, CEO and Co-Founder of Kate Therapeutics, to hook an investor and grow from his garage to 45 people during the pandemic.
“This year is going to end up probably better than 2019,” said Asish Xavier, VP of Venture Investments at Johnson & Johnson Innovation. “I know it feels like a downmarket compared to 2021, but the COVID era was an aberration. It’s still a good fundraising environment for all stages of companies.”
Why we’re optimistic: “At the end of the day, despite all the craziness in the world right now, this is an innovation, glass-half-full, optimist’s industry,” concluded Forrest. “Everybody here is doing important stuff. We are trying to change the world for patients.” Read more at Bio.News. |
|
|
Good Day BIO Live at BIF: ‘Series B means be in the clinic’ |
|
|
|
Jonathan Norris, Managing Director at HSBC Innovation, talks about increased expectations for early-stage companies. |
|
|
|
|
USITC: ‘No credible evidence’ for expanding WTO’s IP waiver |
|
|
A government report “reiterates our stance that there is no credible evidence supporting the need for an expanded TRIPs waiver,” says BIO. ICYMI: After agreeing to waive WTO intellectual property protections of COVID-19 vaccines in June 2022, the U.S. Trade Representative (USTR) is considering a proposal to expand the waiver to COVID-19 diagnostics and therapeutics. USTR asked the U.S. International Trade Commission (USITC) to produce a report on the proposal. USITC’s report, released yesterday, finds no evidence to support a WTO IP waiver expansion “or other expansions that would hinder critical intellectual property protections within the biomedical field,” says BIO Chief Policy Officer John Murphy. BIO’s view: “Innovation and intellectual property go hand-in-hand,” says Murphy. “We will continue to work with this Administration to find solutions that encourage innovation within the life sciences fields and increase patient access to critical diagnostics, therapeutics, and vaccines.” What’s next: BIO is conducting a full analysis of the USITC’s 497-page report. Watch this space for details. |
|
|
|
Good Day BIO Live at BIF: ‘Let’s get these companies started’ |
|
|
|
Stephanie Marrus, Managing Director of Entrepreneurship at the University of California San Francisco (UCSF), discusses why and how tech transfer should be business-friendly. |
|
|
How to follow the BIO Investor Forum
|
|
|
|
|
|
|
|
President Biden’s Wednesday: Landing in Israel this morning for a mission that was altered by an explosion at a Gaza hospital that killed hundreds, AP reports. What’s Happening on Capitol Hill: The House is working to choose a new Speaker today. The Senate’s Health, Education, Labor, and Pensions Committee will discuss the nomination of Monica Bertagnolli to be Director of the National Institutes of Health. |
|
|
|
|
